@article{MTMT:34760472,
	title = {Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis},
	url = {https://m2.mtmt.hu/api/publication/34760472},
	author = {Bérczi, Bálint and Borbásné Farkas, Kornélia and Hegyi, Péter and Tóth, Barbara and Csupor, Dezső and Németh, Balázs and Lukács, Anita and Czumbel, László Márk and Kerémi, Beáta and Kiss, István and Szabó, Andrea and Varga, Gábor and Gerber, Gábor and Gyöngyi, Zoltán},
	doi = {10.3390/jcm13061818},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {13},
	unique-id = {34760472},
	abstract = {Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.},
	year = {2024},
	eissn = {2077-0383},
	orcid-numbers = {Borbásné Farkas, Kornélia/0000-0002-5349-6527; Hegyi, Péter/0000-0003-0399-7259; Tóth, Barbara/0000-0002-6086-8819; Csupor, Dezső/0000-0002-4088-3333; Németh, Balázs/0000-0002-4914-9872; Lukács, Anita/0000-0002-0746-8920; Czumbel, László Márk/0000-0002-5915-0383; Kerémi, Beáta/0000-0003-4000-9440; Szabó, Andrea/0000-0003-4949-9431; Varga, Gábor/0000-0002-5506-8198; Gerber, Gábor/0000-0003-0256-2608; Gyöngyi, Zoltán/0000-0001-9330-9119}
}

@article{MTMT:34496994,
	title = {The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence. a systematic review and meta-analysis of randomized clinical trials},
	url = {https://m2.mtmt.hu/api/publication/34496994},
	author = {Laczkó-Zöld, Eszter and Csupor-Löffler, Boglárka and Kolcsár, Edina-Blanka and Ferenci, Tamás and Nan, Monica and Tóth, Barbara and Csupor, Dezső},
	doi = {10.3389/fnut.2023.1200801},
	journal-iso = {FRONT NUTR},
	journal = {FRONTIERS IN NUTRITION},
	volume = {10},
	unique-id = {34496994},
	issn = {2296-861X},
	abstract = {Several studies have shown that Momordica charantia L. (Cucurbitaceae, bitter melon) has beneficial effects on metabolic syndrome (MetS) parameters and exerts antidiabetic, anti-hyperlipidemic, and anti-obesity activities. Since the findings of these studies are contradictory, the goal of this systematic review and meta-analysis was to assess the efficacy of bitter melon in the treatment of metabolic syndrome, with special emphasis on the anti-diabetic effect. Embase, Cochrane, PubMed, and Web of Science databases were searched for randomized controlled human trials (RCTs). The meta-analysis was reported according to the PRISMA statement. The primary outcomes of the review are body weight, BMI, fasting blood glucose, glycated hemoglobin A1c, systolic blood pressure, diastolic blood pressure, serum triglyceride, HDL, LDL, and total cholesterol levels. Nine studies were included in the meta-analysis with 414 patients in total and 4–16 weeks of follow-up. In case of the meta-analysis of change scores, no significant effect could be observed for bitter melon treatment over placebo on fasting blood glucose level (MD = −0.03; 95% CI: −0.38 to 0.31; I 2 = 34%), HbA1c level (MD = −0.12; 95% CI: −0.35 to 0.11; I 2 = 56%), HDL (MD = −0.04; 95% CI: −0.17 to 0.09; I 2 = 66%), LDL (MD = −0.10; 95% CI: −0.28 to 0.08; I 2 = 37%), total cholesterol (MD = −0.04; 95% CI: −0.17 to 0.09; I 2 = 66%,), body weight (MD = −1.00; 95% CI: −2.59–0.59; I 2 = 97%), BMI (MD = −0.42; 95% CI: −0.99–0.14; I 2 = 95%), systolic blood pressure (MD = 1.01; 95% CI: −1.07–3.09; I 2 = 0%) and diastolic blood pressure levels (MD = 0.24; 95% CI: −1.04–1.53; I 2 = 0%). Momordica treatment was not associated with a notable change in ALT, AST, and creatinine levels compared to the placebo, which supports the safety of this plant. However, the power was overall low and the meta-analyzed studies were also too short to reliably detect long-term metabolic effects. This highlights the need for additional research into this plant in carefully planned clinical trials of longer duration.},
	year = {2024},
	eissn = {2296-861X},
	orcid-numbers = {Ferenci, Tamás/0000-0001-6791-3080; Tóth, Barbara/0000-0002-6086-8819; Csupor, Dezső/0000-0002-4088-3333}
}

@article{MTMT:34728728,
	title = {Storage Conditions Influence the Quality of Ginger – A Stability Study Inspired by Clinical Trials},
	url = {https://m2.mtmt.hu/api/publication/34728728},
	author = {Tóth, Barbara and Horváth, Attila and Jójártné Laczkovich, Orsolya and Biró, Dalma and Matuz, Mária and Csupor, Dezső},
	doi = {10.1055/a-2283-8147},
	journal-iso = {PLANTA MED},
	journal = {PLANTA MEDICA: NATURAL PRODUCTS AND MEDICINAL PLANT RESEARCH},
	unique-id = {34728728},
	issn = {0032-0943},
	abstract = {Ginger has traditionally been used to treat and prevent nausea and vomiting; however, the results of clinical trials are ambiguous. The efficacy of ginger is attributed to gingerols and their metabolites, shogaols. Since these compounds have different pharmacological profiles, the clinical efficacy of ginger products is largely dependent on their chemical composition. The goal of our study was to examine the stability of ginger determining the 6-gingerol contents in order to assess the effects of different storage conditions. We have performed a 6-month stability test with dry ginger rhizome samples stored in a constant climate chamber in three different storage containers (uncovered glass container, glass container sealed with rubber stopper, plastic container). 6-gingerol contents were measured by HPLC method. The concentration of 6-gingerol decreased in all samples. In the sealed glass container, the decrease of 6-gingerol content was significantly lower than in the unsealed glass container and in the plastic container. These results demonstrate that storage conditions have a significant impact on the quality of ginger, which may also affect efficacy.},
	year = {2024},
	eissn = {1439-0221},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819; Matuz, Mária/0000-0002-7877-2399; Csupor, Dezső/0000-0002-4088-3333}
}

@CONFERENCE{MTMT:34074613,
	title = {Synephrine: useful tool to promote weight loss or a possible source of cardiovascular risk?},
	url = {https://m2.mtmt.hu/api/publication/34074613},
	author = {Tóth, Barbara and Koncz, Dorottya and Bahar, Muhammad Akbar and Roza, Orsolya and Csupor, Dezső},
	booktitle = {EuroDURG Conference 2023},
	unique-id = {34074613},
	year = {2023},
	pages = {84-84},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819; Roza, Orsolya/0000-0001-7928-0305; Csupor, Dezső/0000-0002-4088-3333}
}

@article{MTMT:33695397,
	title = {Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection.},
	url = {https://m2.mtmt.hu/api/publication/33695397},
	author = {Ragó, Zsuzsanna and Tóth, Barbara and Szalenko-Tőkés, Ágnes and Bella, Zsolt and Dembrovszky, Fanni and Borbásné Farkas, Kornélia and Kiss, Szabolcs and Hegyi, Péter and Matuz, Mária and Crul-Tóth, Noémi and Hegedüs, Imre and Máthé, Domokos and Csupor, Dezső},
	doi = {10.1007/s11357-023-00756-y},
	journal-iso = {GEROSCIENCE},
	journal = {GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)},
	volume = {45},
	unique-id = {33695397},
	issn = {2509-2715},
	abstract = {Ivermectin, an antiparasitic drug, has been repurposed for COVID-19 treatment during the SARS-CoV-2 pandemic. Although its antiviral efficacy was confirmed early in vitro and in preclinical studies, its clinical efficacy remained ambiguous. Our purpose was to assess the efficacy of ivermectin in terms of time to viral clearance based on the meta-analysis of available clinical trials at the closing date of the data search period, one year after the start of the pandemic. This meta-analysis was reported by following the PRISMA guidelines and by using the PICO format for formulating the question. The study protocol was registered on PROSPERO. Embase, MEDLINE (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), bioRvix, and medRvix were searched for human studies of patients receiving ivermectin therapy with control groups. No language or publication status restrictions were applied. The search ended on 1/31/2021 exactly one year after WHO declared the public health emergency on novel coronavirus. The meta-analysis of three trials involving 382 patients revealed that the mean time to viral clearance was 5.74 days shorter in case of ivermectin treatment compared to the control groups [WMD = -5.74, 95% CI (-11.1, -0.39), p = 0.036]. Ivermectin has significantly reduced the time to viral clearance in mild to moderate COVID-19 diseases compared to control groups. However, more eligible studies are needed for analysis to increase the quality of evidence of ivermectin use in COVID-19.},
	keywords = {Meta-analysis; systematic review; ivermectin; COVID-19; SARS-CoV-2},
	year = {2023},
	eissn = {2509-2723},
	pages = {2179-2193},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819; Dembrovszky, Fanni/0000-0001-6953-3591; Borbásné Farkas, Kornélia/0000-0002-5349-6527; Hegyi, Péter/0000-0003-0399-7259; Matuz, Mária/0000-0002-7877-2399; Hegedüs, Imre/0000-0002-1438-3511; Csupor, Dezső/0000-0002-4088-3333}
}

@article{MTMT:34398458,
	title = {Tea, kávé, csokoládé: finomak és egészségesek},
	url = {https://m2.mtmt.hu/api/publication/34398458},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398458},
	issn = {1789-9478},
	year = {2023},
	pages = {8-10},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398456,
	title = {Gyógynövények a bélben},
	url = {https://m2.mtmt.hu/api/publication/34398456},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398456},
	issn = {1789-9478},
	year = {2023},
	pages = {7-9},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398454,
	title = {Máriatövis. Nemcsak májvédelemre},
	url = {https://m2.mtmt.hu/api/publication/34398454},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398454},
	issn = {1789-9478},
	year = {2023},
	pages = {10-11},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398452,
	title = {Kurkuma. Fűszernövényből gyógyszer},
	url = {https://m2.mtmt.hu/api/publication/34398452},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398452},
	issn = {1789-9478},
	year = {2023},
	pages = {13-15},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398451,
	title = {Mire jó a C-vitamin?},
	url = {https://m2.mtmt.hu/api/publication/34398451},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398451},
	issn = {1789-9478},
	year = {2023},
	pages = {10-12},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}